Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC(TM) for Treatment of ICU COVID-19 Patients
-- First three patients
discharged from Hospital ICU within 8 days from initial
IV administration
-- No infusion-related adverse events noted for any patient treated to date
SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC(TM)) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 10(6) cells/kg. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS. The secondary objective is to evaluate efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.
The first three patients enrolled tolerated treatment well and improved rapidly. Each of the three patients was discharged from the hospital within a week of starting the patient's COVI-MSC infusions and two patients were discharged on the day of their last infusion. One of the patients had been in the hospital for three weeks, unable to be weaned from significant oxygen support, and another patient with uncontrolled diabetes had been discharged previously but had to be readmitted due to recurrent ARD. Each of the infusions were well-tolerated and no patient reported any infusion-related adverse events. A fourth patient is currently at the beginning of a course of treatment, with no safety issues following the patient's first infusion. Additional enrollment continues.
Dr. Eyad Almasri, Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine at UCSF Fresno, is the principal investigator in this ongoing study. Dr. Almasri stated, "I am excited to see how well-tolerated this promising treatment is to date and am very encouraged by the early signals we are seeing from the first few patients. I am looking forward to working with Sorrento in continuing to offer COVI-MSC treatments to patients in this study and in the proposed controlled phase 2 study."
T2 Biosystems: Term Loan Agreement Extends Interest-Only and Principal Payment Periods to Dec 31, 2022
T2 Biosystems Sees Q4 2020 Revenue $7.8 million
BY Reuters
— 4:46 PM ET 01/26/2021
Jan 26 (Reuters) - T2 Biosystems Inc ( TTOO ):
* T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2020 RESULTS
* SEES Q4 2020 REVENUE $7.8 MILLION
* SEES FY 2020 REVENUE $18.1 MILLION
* Q4 REVENUE VIEW $9.0 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
$3.35 AH!
TTOO up 33%
VXRT up $3.35
TTOO $2.11
TTOO, VXRT running
TTOO here we go!
VXRT on high alert....
$1.99 !!
First of many has been placed for 4800. Short interest only 13% today. Get ready for a big move...
SRNE, INO & TTOO all Buys here
INO about to go parabolic. $40
$4-5 coming soon for TTOO
$4-5 coming soon for TTOO
INO huge announcement soon
$4-5 coming soon for TTOO
* * $SRNE Video Chart 01-19-2021 * *
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161036278
TTOO $1.94 AH, SRNE $10.16 AH
TTOO $1.94 AH, SRNE $10.16 AH
TTOO $1.94 AH, SRNE $10.16 AH
What ever he said last week worked! Up 3 points
Its an empty shell.
INO, SRNE and TTOO all on high alert
Shorts are going to need a lot of toilet paper soon!
Shorts are going to need a lot of toilet paper soon!
Shorts are going to need a lot of toilet paper soon!
Seeking Alpha is a 3rd rate publication. Total garbage
SRNE moving
What are talking about INO and JNJ are in the same testing stage. INO4800 is the vaccine
Thanks Clay
* * $TTOO Video Chart 01-12-2021 * *
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160872818